This is an aggregated industry headline. Read the full story at BioPharma Dive →
TRex Bio prices $117M IPO to support immune drug work
Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating "Treg" cells.
By BioPharma Dive
· Oct 9, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekBriefing
AJMC reported that Medicare drug price negotiations are yielding uneven out-of-pocket savings. The policy sign…
The WeekPharmaceutical Technology ↗
China's NMPA has approved the MAA for Foresee Pharmaceuticals' Camcevi 42 mg to treat adult patients with adva…
The WeekKFF Health News ↗
Health care's AI future is being built right now. The open question is "for whom?" Dr. Uché Blackstock - emerg…